Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medivation, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or older and willing and able to provide informed consent;
Histologically confirmed relapsed or refractory CD20+ DLBCL, transformed indolent lymphoma (follicular or other), or primary mediastinal large B-cell lymphoma;
Received prior treatment with a standard anthracycline and therapeutic anti-CD20 monoclonal antibody-based regimen;
For transplant-ineligible patients, salvage therapy just prior to MDV9300 treatment must have resulted in a PR or stable disease;
For post autologous stem cell transplant (ASCT) patients, salvage therapy plus ASCT just prior to MDV9300 treatment must have resulted in a PR or stable disease;
Adequate bone marrow reserve as defined per protocol;
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Patients with stable ECOG scores of 2 may be allowed with medical monitor approval.
You may not be if
Burkitt, mantle cell, follicular, or mucosa-associated lymphoid tissue lymphoma
History of serious autoimmune disease;
History of central nervous system involvement of lymphoma;
Prior therapy with agents targeting immune coinhibitory receptors.
